OBJECTIVE: Leptin regulates energy production rates and body weight, which are frequently altered in hyperthyroidism. Data on a possible interaction between leptin and thyroid hormones are controversial. We assessed leptin serum concentrations, BMI, proportional fat tissue mass and thyroid hormones in hyperthyroid patients in a long-term follow-up after radioiodine therapy. DESIGN: The study included 28 hyperthyroid patients (mean age 66 y) before and up to one y after radioiodine therapy. Leptin and thyroid hormones, general parameters, BMI, proportional fat tissue (PFT) measurements by DEXA and thyroid morphology were recorded. Twenty-four age-matched euthyroid individuals (mean age 63 y) served as controls. RESULTS: At baseline, leptin concentrations were signi®cantly decreased in all hyperthyroid patients as compared to controls. One year after radioiodine therapy, 71% of the patients were euthyroid (group A) and 29% remained hyperthyroid (group B). BMI and PFT increased in both groups. While leptin concentrations remained low in group B, they normalised in group A after 6 to 12 months. Changes in leptin and thyroid hormone concentrations were positively correlated in group A patients (r 0.49, P 0.03) but not in patients remaining hyperthyroid. CONCLUSION: Our data indicate a dissociation in the regulation of plasma leptin and BMI as well as proportional fat tissue in hyperthyroid patients which may be attributable to differences in lean and adipose mass weight gain after radioiodine therapy or direct in¯uences of thyroid hormones on leptin regulation.
Introduction
Energy balance and body weight are mainly controlled by leptin, a proteohormone produced mainly by adipocytes 1, 2 encoded by the ob gene. Leptin values correlate signi®cantly with anthropometric parameters that characterise physical constitution and the amount of subcutaneous adipose tissue. Leptin interacts with putative receptors in the hypothalamus decreasing appetite, increasing energy expenditure and regulating body weight. 3 Leptin is known to be in¯uenced by other hormones including insulin, 4 glucocorticoids, 5 b-adrenergic stimulation 6 or by cytokines 7 and is known to be different in men and women, 8 with higher levels in women. The complex interaction of leptin with hormones is as yet not fully understood, and the interaction between leptin and thyroid hormones in particular is still controversial. 9 ± 23 Hyperthyroidism alters metabolic rates and thermogenesis, energy expenditure as well as body weight and appetite. 24 It might therefore be expected that thyroid hormones would have an in¯uence on the leptin system. In vitro studies have shown that physiological concentrations of T 3 increase leptin expression. 9 This was con®rmed by human experiments. 3, 10 Elevated plasma leptin values were reported in hyperthyroid patients, 11,12 decreased plasma leptin values in hypothyroid patients, 13, 14 but other studies showed no in¯u-ence of altered thyroid function 15 ± 17 or hyperthyroidism 18 on plasma leptin concentrations. Healthy volunteers showed no short-term in¯uences of thyroid function on leptin concentrations. 21 In contrast, elevated plasma leptin was reported in hypothyroid animals 19, 20 and hypothyroid patients 18, 22 and decreased levels in thyrotoxic patients as compared to euthyroid controls. 23 The present study assessed, in hyperthyroid patients, the in¯uence of radioiodine therapy on thyroid function, plasma leptin concentrations and body mass index (BMI) as well as proportional fat tissue (PFT) during a one-year follow-up.
Methods
Twenty-eight consecutive patients (23 female and 5 male, mean age 66 y, range 52 ± 82) referred to our thyroid outpatient clinic for radioiodine therapy with newly diagnosed mild hyperthyroidism, ie suppressed TSH concentrations (reference range 0.1 ± 4 mUal), slightly elevated serum concentrations of thyroid hormones (free thyroxine, fT4 reference range 9 ± 23 pmolal and free triiodothyronine, fT3, reference range 3 ± 6.3 pmolal) and moderate clinical symptoms of hyperthyroidism were included in the study. Exclusion criteria were severe obesity (BMI b 27), diabetes, and any hormonal disorder other than hyperthyroidism or any medication known to in¯uence thyroid metabolism. All were non-smokers. Thyroid function, BMI and leptin concentrations were followed in all patients for one year. Twenty-four age-matched healthy controls (22 women and 2 men, mean age 63 y, range 51 ± 80) with BMI below 27 were included.
Hyperthyroidism was diagnosed by clinical examination, 99m Tc-thyroid scan, thyroid sonography, and thyroid hormone levels. Hyperthyroid patients had toxic adenomas or multinodular toxic goitre; cases of Graves' disease were excluded by scintigraphic criteria and thyrotropin receptor antibodies. BMI (ie weight in kilograms divided by the square of the height in meters), physical examination and a complete medical history were recorded on the day that patients and controls were enrolled. The euthyroid state was de®ned as normal TSH combined with fT3 and fT4 in the normal range.
Standardised dual energy x-ray absorptiometry (DEXA, Sophos, France) at the lumbar spine (L2 ± L4) was performed in all patients at baseline and in half of the patients at the end of the observation period; bone mineral content and measurements of proportional fat tissue were included (PFT). PFT values derive from the natural logarithm of the ratios of the attenuated and the unattenuated x-ray beam intensities used during DEXA measurements. PTF is supposed to be linearly related to the proportional fat component 25 and was used as a surrogate for proportional fat tissue mass. This study is admittedly limited by the fact that it was not possible to measure whole body fat and mineral content for technical reasons. Measurements of bone mineral density were expressed as gacm 2 at the de®ned area. The coef®cient of variation of repeated measurements was 2.2%.
Venous blood samples were drawn between 8 and 9 am after an overnight fast (Vacutainer System, Beckton Dickinson). Hormones were measured using commercial radioimmunological kits: TSH and fT3 (both from Behring, Marburg, Germany), fT4 (Beckton & Dickinson, San Francisco, USA), and leptin (LincoResearch, Inc, St Charles, MO, USA). The detection limit of the leptin assay was 0.5 ngaml at the lowest levels and 100 ngaml at the highest. Intra-assay coef®cient of variation (CV) for the leptin assay was 3.2%, interassay CV was 5.1%. Serum for hormone measurements was kept frozen at 770 C until determination. Routine blood work (Auto-Analyser) (fasting glucose, cholesterol, triglycerides, kidney and liver function tests) was done on the same day to exclude secondary bone disease.
131 I-dosage for each patient was estimated according to thyroid gland size and thyroid-tissue- 99 Tc-uptake and averaged 6.7 AE 1.1 mCi (249 AE 41 MBq) of 131 I. After written informed consent was obtained, patients were examined on the day of 131 I administration, and blood samples were drawn. On scheduled visits at 1 day, one week, three and six months and one year after treatment, patients were re-examined and further blood samples were obtained. Patients were evaluated retrospectively according to the results of radioiodine therapy with restitution of euthyroid function (group A, n 20) or persistence of hyperthyroidism (group B, n 8).
Statistical methods included two-tailed t-tests for dependent or independent variables. Chi square test, Wilcoxon's and Mann ± Whitney-U-tests were performed as appropriate depending on normal distribution and variance of the parameters. Regression analysis and ANOVA were performed using statistics programs for the PC (SPSS version 8.0, Sigmastat and Sigmaplot). If not otherwise indicated, the results are expressed as range or mean AE standard deviation (s.d.). P`0.05 is regarded as signi®cant for all analyses.
Results
The general parameters of patients and controls are summarized in Table 1 . There were no signi®cant differences in age, gender, BMI, and PFT between the two groups. Initial thyroid hormone concentrations were signi®cantly higher and TSH was signi®cantly lower in hyperthyroid patients than in controls.
Leptin concentrations were signi®cantly lower in hyperthyroid patients (7.3 AE 5.4, P 0.006) as compared to controls (11.5 AE 6.3, Figure 1 ).
In controls, leptin concentrations correlated to BMI indices (r 0.58, P 0.002) and TSH concentrations (r 0.44, P 0.02), but not with PFT values (r 0.3, Leptin in hyperthyroidism BM Obermayer-Pietsch et al Figure 1 Leptin concentrations were signi®cantly decreased in all hyperthyroid patients (7.3 AE 5.4, P`0.006) as compared to age-and BMI-matched euthyroid healthy controls (11.5 AE 6.3). Depending on thyroid function one year after radioiodine therapy, patients were subdivided into a group with restoration of euthyroid status (group A, n 20) and a group which remained hyperthyroid (group B, n 8). BMI and PFT (proportional fat tissue) increased in both groups signi®cantly, but leptin increased only in patients who became euthyroid. Patients who remained hyperthyroid showed no effect of body weight and PFT gain on plasma leptin concentrations. Figure 2 We compared leptin plasma concentrations, BMI, proportional fat tissue (PFT) and fT3 concentrations in patients with normalised thyroid function after radioiodine therapy at baseline and one year after therapy. BMI, PFT and leptin concentrations showed a signi®cant increase, whereas fT3 decreased signi®cantly to the normal range.
Leptin in hyperthyroidism BM Obermayer-Pietsch et al P 0.28), fT3 (r 7 0.04, P 0.84) or fT4 (r 0.07, P 0.74) concentrations. In hyperthyroid patients, correlation analyses between leptin concentrations and either fT3, fT4, TSH, BMI or PFT were not signi®cant (P b 0.26 for all correlations). One year after radioiodine therapy, 20 patients were found to be euthyroid (group A, 71%) and 8 had remained hyperthyroid (group B, 29%). Table 2 summarises these results.
Group A patients showed signi®cant increases in TSH, BMI, PFT and plasma leptin concentrations and signi®cant decreases in fT3 and fT4 (Figure 2) . Their changes in fT3 correlated signi®cantly with the changes in leptin (r 0.49, P 0.03).
Group B patients showed slight, but not signi®cant decreases in fT3 and fT4, and a small, but not signi®cant increase in TSH. Leptin concentrations remained unchanged in group B, despite BMI, and PFT indices showed a signi®cant increase (Figure 3 ). There was no correlation between changes in leptin and changes of thyroid function.
In patients of group A leptin concentrations normalised between 6 months and one year after radioiodine therapy (Figure 4) , whereas fT3 concentrations normalised after one week to three months. Figure 3 Leptin plasma concentrations, BMI, PFT and fT3 concentrations of patients who remained hyperthyroid one year after radioiodine therapy are shown at baseline and one year after therapy. BMI and PFT showed a signi®cant increase, but leptin and fT3 concentrations remained unchanged (normal range of fT3 (3 ± 6.3 pmolal)).
Figure 4
Leptin plasma concentrations in patients with restoration of thyroid function, measured at baseline, one day, one week, three months, six months and one year after radioiodine therapy. Patients, who remained hyperthyroid, had no changes in plasma leptin concentrations (data not shown). 
Discussion
This study demonstrates a dissociation of leptin values and BMI as well as proportional fat tissue (PFT) in patients who remained hyperthyroid after radioiodine treatment (group B). This was shown by a signi®cant increase in BMI and PFT values which was not paralleled by an increase in plasma leptin concentrations (Figure 3) . In group A patients, an increase of mean BMI (23.3 to 24.8, P`0.05) and PFT values (20.5 to 22.2, P`0.02) was accompanied by the normalisation of previously low leptin concentrations. BMI is known to rise signi®cantly (20.2%, P`0.0005) in patients becoming euthyroid within one year after radioiodine therapy. 26 They may have a weight gain between 6 and 16%, 27 as shown in our patients (6 to 13%, respectively). However, changes in bone mineral density may not signi®cantly contribute to this weight gain in our patients, as suggested by lumbar mineral density measurements.
Our results indicate that hyperthyroidism causes a decrease of plasma leptin in patients with comparable BMI and proportional fat tissue mass, contradicting several other reports. 12,13,15 ± 17 In human studies, plasma leptin concentrations have been found to be unchanged, 15 ± 17 elevated, 11, 12 or decreased 3, 23 in hyperthyroidism. These controversial results may be due to differences in gender, ethnicity, BMI, nutrition preceding blood sampling and the time of day of the latter. However, acute weight losses in our patients prior to the diagnosis of hyperthyroidism may have caused the low leptin concentrations, since weight losses over 3 months in euthyroid subjects are known to cause low leptin concentrations. 28 A previous longitudinal study on leptin concentrations in hypo-and hyperthyroidism 10 reported an increase of leptin concentrations after treatment of both hyperthyroidism and hypothyroidism. Since post-therapeutic euthyroidism was differently de®ned and euthyroid controls were not included, the results may not be directly comparable. Another recent study on hyperthyroid patients receiving thiamazole treatment also showed decreased leptin concentrations at baseline, which increased during one year of therapy without a signi®cant and corresponding degree of changes in total fat mass. 23 Low leptin concentrations following loss of weight and adipose tissue in these patients may correspond to our observation. However, these patients were younger and received thiamazole as antithyroid medication, which induces substantial differences in the timecourse of post-therapeutic euthyroidism as compared to radioactive treatment. Furthermore, changes in leptin or thyroid receptors caused by radioactive treatment cannot be excluded and should be addressed by further studies.
In our patients, plasma leptin concentrations normalised within 6 months to one year, whereas thyroid function had already normalised between three and six months after radioiodine treatment. This indicates that plasma leptin concentrations may be in¯uenced by thyroid function over a longer period than expected. To our knowledge, data are scarce on possible long-term effects of thyroid hormones on leptin concentrations, 28 since studies on disorders of thyroid function and leptin usually end with euthyroidism.
11, 14, 16, 21 The blood serum level of leptin is assumed to indicate reliably the amount of a person's adipose tissue. In the present study, the blood serum values of leptin paralleled the body mass indices and PFT values of controls and those hyperthyroid patients who had become euthyroid one year after radioiodine therapy. However, patients who remained hyperthyroid showed increases in body mass that were not paralleled by increases in serum leptin. This gain in body mass and proportional fat tissue is thus likely to be due to factors other than an increase in leptin.
However, we were not able to measure changes in whole body lean and fat mass distribution in our patients, as should be done in further prospective studies to clarify these complex processes.
